• J Gen Intern Med · Feb 2022

    Review

    Factors Associated with Long-Term Retention in Buprenorphine-Based Addiction Treatment Programs: a Systematic Review.

    • Amy J Kennedy, Charles B Wessel, Rebecca Levine, Kendall Downer, Megan Raymond, Deborah Osakue, Iman Hassan, Jessica S Merlin, and Jane M Liebschutz.
    • Ambulatory Care Network, Department of Health Services, Los Angeles County, Los Angeles, CA, USA.
    • J Gen Intern Med. 2022 Feb 1; 37 (2): 332340332-340.

    BackgroundThe average length of buprenorphine treatment for opioid use disorder is less than 6 months.ObjectiveWe conducted a systematic review to determine what factors were associated with longer retention in buprenorphine treatment.DesignWe searched Medline, Embase, and Cochrane Database of Systematic Reviews in February 2018. Articles were restricted to randomized controlled trials on human subjects, written in English, which contained ≥ 24 weeks of objective data on retention in buprenorphine treatment.Main MeasuresWe assessed whether dose of buprenorphine, treatment setting, or co-administration of behavioral therapy was associated with retention rates.Key ResultsOver 14,000 articles were identified. Thirteen articles (describing 9 studies) met inclusion criteria. Measures of retention varied widely. Three studies compared doses of buprenorphine between 1 and 8 mg and showed significantly higher rates of retention with higher doses (p values < 0.01). All other studies utilized buprenorphine doses between 8 and 24 mg daily, without comparison. No study found a significant difference in retention between buprenorphine alone and buprenorphine plus behavioral therapy (p values > 0.05). Initiating buprenorphine while hospitalized or within criminal justice settings prior to outpatient treatment programs was significantly associated with retention in buprenorphine treatment (p values < 0.01 respectively).ConclusionsSetting of treatment initiation and a higher buprenorphine dose are associated with improved long-term treatment retention. More objective data on buprenorphine treatment programs are needed, including a standardized approach to defining retention in buprenorphine treatment programs.RegistrationThis review was registered with PROSPERO (#CRD42019120336) in March 2019.© 2021. Society of General Internal Medicine.

      Pubmed     Free full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…